New pill aims to keep rare lymphoma in check after chemo

NCT ID NCT07300514

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 19, 2026 · Updated 19 times

Summary

This study tests a drug called golidocitinib as a maintenance treatment for people with peripheral T-cell lymphoma (PTCL) whose cancer improved or disappeared after initial chemotherapy. About 136 adults who cannot or choose not to have a stem cell transplant will take either the drug or a placebo for up to 2 years. The goal is to see if the drug helps delay the cancer from returning.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) MAINTENANCE TREATMENT OF PERIPHERAL T-CELL LYMPHOMA PERIPHERAL T-CELL LYMPHOMA (PTCL NOS) T-FOLLICULAR HELPER PHENOTYPE PERIPHERAL T-CELL LYMPHOMA